Italy bans antibiotic APIs made by Antibioticos do Brasil

By Gareth Macdonald contact

- Last updated on GMT

Antibioticos do Brasil LTDA (ABL) facility in Bairro Itapavussu, Sao Paulo
Antibioticos do Brasil LTDA (ABL) facility in Bairro Itapavussu, Sao Paulo

Related tags: São paulo

Italy has banned APIs made by Antibioticos do Brasil LTDA (ABL) at its facility in Bairro Itapavussu, Sao Paulo over sterility concerns.

According to a post on EudraGDMP​, the AIFA team who visited the site last month found problems with maintenance, environmental monitoring and cleaning procedures used in areas where antibiotics like cephalexin sodium are made.

The regulator also said staff demonstrated little awareness of European good manufacturing practice (GMP) standards and raised concerns about the lack of coverage of the topic in training programmes.

It was noted that a specific training on European GMP (Eudralex vol. 4) was not scheduled; neither a gap analysis between Brazilian and European GMP was performed in order to verify the overlapping of the two guidelines​.”

The quality control laboratory at the site was also the subject of criticism.

AFIA said: “The design of the QC microbiological laboratory failed to maintain a rationale material flow in order to prevent a potential contamination during the testing performance​.”


In addition to prohibiting the supply of drug substances and bulk drug products made at the site, AIFA urged the European Directorate for the Quality of Medicines (EDQM) to suspend ABL’s certificate of suitability (CEP) for Ceftazidime pentahydrate with sodium carbonate.

The Rome-based regulator also said that: “Due to the number and nature of raised deficiencies, a new GMP inspection is needed, even if a CAPA plan is submitted, in order to assess effective removal of deficiencies​.”

ABL did not respond to a request for comment.

The AFIA comments come just a month after the US Food and Drug Administration (FDA) published a warning letter​ it sent to the Brazilian firm.

The document details a number of quality problems identified by the US regulator during a visit to the firm's facility last April.

Related news

Show more

Related products

show more

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us


View more